Founder and CEO of US online social media and social networking service Facebook Mark Zuckerberg. Photo by KENZO TRIBOUILLARD/AFP via Getty Images/FILE)
Mark Zuckerberg and his wife Priscilla Chan have donated $25 million through their foundation to a philanthropic effort organized by Bill Gates to explore new coronavirus treatments.
The Gates Foundation donated $50 million last week to what it’s calling the “COVID-19 Therapeutics Accelerator.” The initiative brings together life sciences companies to collaborate on the development of new vaccines, diagnostics, and treatments for COVID-19.
“The Therapeutics Accelerator will enable researchers to quickly determine whether or not existing drugs have a potential benefit against COVID-19,” Chan and Zuckerberg said in a press release. “We hope these coordinated efforts will help stop the spread of COVID-19 as well as provide shared, reusable strategies to respond to future pandemics.”
The two donations are the largest from tech billionaires since the coronavirus outbreak. Wellcome and Mastercard are supporting the effort as well.
The goal of the initiative is to either develop a new drug or adapt an existing treatment that it could help distribute alongside partnering pharmaceutical companies.
The 15 companies participating in the project kicked off the effort by sharing their proprietary libraries of molecular compounds that have some history of being tested with COVID-19.
The lineup includes big names in biotech such as Johnson & Johnson, Merck, Pfizer, Sanofi, and Bristol-Myers Squibb.
Tech titan Microsoft reported its second fiscal quarter of 2022 earnings on Tuesday, its first earnings report since announcing its plans to acquire gaming company Activision Blizzard in a multibillion dollar deal. Steve Larsen, co-founder of PlannerDAO, explains the role that cloud services played for Microsoft in the quarter and what the future may hold for Microsoft in the midst of the new acquisition.
Microsoft is expected to report financial results for its second fiscal quarter of 2022. It comes after the company beat on its top and bottom line in its previous four quarters. John Freeman of CFRA Research explains what investors will be keeping an eye out for as Microsoft continues to expand its domain.
High-speed connectivity solutions provider Credo went public on the Nasdaq on Thursday, raising $200 million in its IPO. CEO Bill Brennan, joined Cheddar to discuss its entry into the capital markets and the next chapter for the company. "We're going to be focused on what we have been focused on, which is really creating, creating innovative connectivity solutions that really pushed the edge on efficient power as well as very effective cost," he said.
BD Veritor is a variation of the at-home COVID test that uses a smartphone to interpret the results. The test is taken via a nose swab test strip that is then scanned by your phone’s camera with the result clearly displayed as positive or negative. James Walker, vice president of integrated diagnostics USA for BD, joined Cheddar to discuss how the test hopefully takes the "guesswork out of testing." Walker also went into what BD is doing to deal with the surging demand for at-home tests amid the omicron spread. "While we don't disclose how much we produce, we have capacity to manufacture up to 12 million rapid antigen tests per month and are delivering on our commitments to distributors and retailers," he said.
Low-code app development platform Crowdbotics raised $22 million in a Series A funding round led by Jackson Square Ventures. Crowdbotics has helped more than 14,000 customers launch apps without having to learn how to code. The company can offer a team of expert developers to help companies launch custom apps, or provide the means for companies to develop apps themselves. Crowdbotics CEO Anand Kulkarni joined Cheddar News' Closing Bell to discuss.
Nathan Harding, CEO of Luum, joins Cheddar Innovates to discuss the process of having a robot put on eyelash extensions, and how automation is making its way into the beauty industry
